D. Boral Capital Downgrades Immunic (NASDAQ:IMUX) to Hold

Immunic (NASDAQ:IMUX) was downgraded by equities research analysts at D. Boral Capital from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Marketbeat.com reports.

A number of other research analysts have also weighed in on the company. Guggenheim assumed coverage on Immunic in a research report on Tuesday, March 24th. They set a “buy” rating and a $7.00 price objective for the company. raised Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Wall Street Zen raised Immunic from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Finally, HC Wainwright reduced their price objective on Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.64.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $1.00 on Wednesday. Immunic has a 52-week low of $0.51 and a 52-week high of $1.51. The firm has a market capitalization of $130.46 million, a P/E ratio of -1.43 and a beta of 1.37. The stock has a 50 day moving average price of $1.08 and a 200-day moving average price of $0.84.

Immunic’s stock is set to reverse split before the market opens on Monday, April 27th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, April 26th.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, equities analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new stake in shares of Immunic in the 4th quarter worth $83,000. Connective Capital Management LLC bought a new stake in shares of Immunic in the 4th quarter worth $161,000. XTX Topco Ltd bought a new stake in shares of Immunic in the 4th quarter worth $120,000. Millennium Management LLC increased its holdings in shares of Immunic by 544.6% in the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock worth $1,825,000 after purchasing an additional 2,888,829 shares in the last quarter. Finally, Laurion Capital Management LP increased its holdings in shares of Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after purchasing an additional 2,000,000 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.